AstraZeneca’s breast cancer drug received a positive opinion from EU regulators, following an FDA advisory committee vote against the drug in April. The EU outcome provides a regulatory path forward in Europe that remains disconnected from the prior US panel result, underscoring how data readouts can translate differently across agencies. The report also noted Novo Nordisk’s Wegovy pill won EU authorization, adding momentum to obesity pharmacotherapy decisions across both markets.